Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC001001 | Panoply™ Human ARVCF Knockdown Stable Cell Line | Inquiry |
| CSC-DC001851 | Panoply™ Human C1D Knockdown Stable Cell Line | Inquiry |
| CSC-DC008852 | Panoply™ Human LRP1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC001001 | Panoply™ Human ARVCF Over-expressing Stable Cell Line | Inquiry |
| CSC-SC001851 | Panoply™ Human C1D Over-expressing Stable Cell Line | Inquiry |
| CSC-SC008852 | Panoply™ Human LRP1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT1764 | C1D Knockout Cell Line-HeLa | Inquiry |
| CLOE-0806 | Human LRP1 HEK293 Cell Lysate | Inquiry |
| CLKO-1610 | C1D KO Cell Lysate-HeLa | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD01401Z | Human Arvcf adenoviral particles | Inquiry |
| LV05553L | human ARVCF (NM_001670) lentivirus particles | Inquiry |
| LV06919L | human C1D (NM_006333) lentivirus particles | Inquiry |
| LV17314L | human LRP1 (NM_002332) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH241018 | shRNA set against Mouse Arvcf (NM_033474.2) | Inquiry |
| SHW005738 | shRNA set against Chicken LRP1 (NM_205242) | Inquiry |
| SHG075305 | shRNA set against Mouse Arvcf(NM_033474.2) | Inquiry |
| SHG118711 | shRNA set against Mouse C1d(NM_020558.3) | Inquiry |
| SHH160967 | shRNA set against Human LRP1(NM_002332.2) | Inquiry |
| SHH160985 | shRNA set against Mouse Lrp1(NM_008512.2) | Inquiry |
| SHH241014 | shRNA set against Human Arvcf (NM_001670.2) | Inquiry |
| SHH250274 | shRNA set against Mouse C1D (NM_020558.3) | Inquiry |
| SHH250278 | shRNA set against Rat C1D (NM_001106021.1) | Inquiry |
| SHH333947 | shRNA set against Human LRP1 (NM_002332.2) | Inquiry |
| SHH333951 | shRNA set against Mouse LRP1 (NM_008512.2) | Inquiry |
| SHW001658 | shRNA set against Chicken C1D (NM_001031036) | Inquiry |
| SHW003461 | shRNA set against Chicken C1D (NM_001244737) | Inquiry |
| SHW004978 | shRNA set against Chicken ARVCF (NM_204465) | Inquiry |
| SHW007515 | shRNA set against Danio rerio C1D (NM_001007059) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| MiUTR3H-08888 | C1D miRNA 3'UTR clone | Inquiry |
| MiUTR3H-04830 | ARVCF miRNA 3'UTR clone | Inquiry |
| MiUTR1M-06743 | LRP1 miRNA 3'UTR clone | Inquiry |
| CDCB167213 | Chicken LRP1 ORF Clone (NM_205242) | Inquiry |
| MiUTR1M-02349 | C1D miRNA 3'UTR clone | Inquiry |
| MiUTR1M-01721 | ARVCF miRNA 3'UTR clone | Inquiry |
| MiUTR1H-05896 | LRP1 miRNA 3'UTR clone | Inquiry |
| CDFR009395 | Rat Arvcf cDNA Clone(NM_001131013.1) | Inquiry |
| CDFR005795 | Rat C1d cDNA Clone(NM_001106021.1) | Inquiry |
| MiUTR3H-08887 | C1D miRNA 3'UTR clone | Inquiry |
| CDCS410749 | Human LRP1 ORF Clone (BC045107) | Inquiry |
| CDCS409195 | Human C1D ORF Clone (BC005235) | Inquiry |
| CDCS409194 | Human C1D ORF Clone (BC009584) | Inquiry |
| CDCR376830 | Rat Arvcf ORF Clone(NM_001131013.1) | Inquiry |
| CDCR280891 | Human ARVCF ORF Clone(NM_001670.2) | Inquiry |
| CDCR030622 | Mouse Arvcf ORF clone (NM_033474.2) | Inquiry |
| CDCL186418 | Human TGF-beta 3 ORF clone(NM_003239.2) | Inquiry |
| CDCL185194 | Human LRP1 ORF clone(NM_002332.2) | Inquiry |
| CDCH388042 | Rat LRP1 ORF clone(NM_001130490.1) | Inquiry |
| CDCH388041 | Mouse LRP1 ORF clone(NM_008512.2) | Inquiry |
| CDCB195474 | Rabbit LRP1 ORF clone (XM_002720944.3) | Inquiry |
| CDCB194787 | Rabbit C1D ORF clone (XM_008254321.1) | Inquiry |
| CDCB185598 | Rabbit ARVCF ORF clone (XM_008250594.1) | Inquiry |
| CDCB168990 | Danio rerio C1D ORF Clone (NM_001007059) | Inquiry |
| CDCB166453 | Chicken ARVCF ORF Clone (NM_204465) | Inquiry |
| CDCB164936 | Chicken C1D ORF Clone (NM_001244737) | Inquiry |
| CDCR372823 | Rat C1d ORF Clone(NM_001106021.1) | Inquiry |
| CDCB163133 | Chicken C1D ORF Clone (NM_001031036) | Inquiry |
Low-density lipoprotein receptor-related protein 1 (LRP1) was first discovered in 1988 through screening mouse lymphocyte and human liver cDNA libraries for sequences homologous to the apoE binding domain of the LDL receptor (LDLR). Compared to LDLR, LRP1 is a structurally massive type I transmembrane protein, encoding 4,525 amino acids and consisting of two subunits: a 515 kDa N-terminal extracellular subunit and an 85 kDa C-terminal transmembrane subunit, which are associated non-covalently. These two subunits are transported to the cell surface after being cleaved by furin enzyme in the trans-Golgi network.
Figure 1. Schematic diagram of domain structure for LRP1 and LDLR. (Shinohara M, et al., 2017)
The extracellular region of LRP1 contains four cysteine-rich ligand-binding domains (I-IV), comprising 2, 8, 10, and 11 complement-type repeats, respectively. Domains II and IV are the primary binding sites for most ligands in the presence of calcium ions. Additionally, its cytoplasmic tail contains multiple NPXY motifs, which are critical signals for mediating endocytosis through clathrin-coated pits, and work in concert with adjacent YXXL and dileucine motifs to achieve rapid internalization. The EGF-like repeats and YWTD β-propeller domains in the extracellular region facilitate the dissociation of ligands in endocytic vesicles.
Effective transport of LRP1 to the cell surface depends on a 39 kDa molecular chaperone—Receptor-Associated Protein (RAP). RAP binds to LRP1 in the early secretory pathway, preventing premature binding with other ligands, and dissociates in the late, low pH environment. RAP, as a universal ligand for LRP1, can block the binding of almost all known LRP1 ligands.
To date, over 40 proteins have been identified as LRP1 ligands, including Aβ, apoE, and activated α2-macroglobulin. However, controversy exists regarding whether Aβ directly binds to domains II and IV of LRP1. While Deane et al. demonstrated in vitro that Aβ (particularly the monomeric form of Aβ40) can bind to these domains, Yamada et al. were unable to reproduce these results in similar experiments. Some studies suggest that LRP1 might depend on other Aβ-binding proteins (such as heparan sulfate proteoglycans) to jointly mediate Aβ internalization. The aggregated or oligomeric forms of Aβ have relatively weaker affinity for LRP1.
Notably, apoE's ability to bind to LRP1 is significantly influenced by its conformation and lipidation state.
Beyond ligand metabolism, LRP1 can also regulate cellular signaling pathways by forming complexes with membrane proteins such as platelet-derived growth factor receptor (PDGF) and N-methyl-D-aspartate receptor (NMDA receptor). Furthermore, LRP1 can be cleaved by β-secretase or α-secretase and γ-secretase, producing intracellular fragments that can act as transcriptional regulatory factors, modulating the expression of multiple genes including interferon-γ, with functions similar to amyloid precursor protein (APP). Simultaneously, the soluble form of LRP1 (sLRP1) also plays an important role in Aβ metabolism.
LRP1 is highly expressed in various tissues, including the liver, brain, and vascular system. Conventional LRP1 knockout mice exhibit early embryonic lethality, in stark contrast to the non-lethal phenotype of LDLR knockout mice. Animal experiments with conditional knockout in hepatocytes, macrophages, adipocytes, and vascular smooth muscle cells indicate that LRP1, by regulating ligand metabolism and signaling pathway intensity, is crucial for tissue development and homeostasis maintenance. Its dysfunction may be associated with diseases such as atherosclerosis and cancer.
Particularly in the nervous system, LRP1 is highly relevant to the pathogenesis of Alzheimer's disease. Animal studies suggest that LRP1 regulates Aβ metabolism and brain homeostasis through multiple pathways, which may depend on apoE subtypes or be independent of apoE. However, since most studies are based on cell or animal models, its specific role in AD remains uncertain. Future research needs to systematically examine: first, changes in LRP1 expression and function at different stages (especially preclinical) in human AD patients; second, the diverse functional roles LRP1 might play in different cell types, ages, disease stages, and apoE subtype backgrounds. These studies will help develop LRP1-targeted therapeutic strategies for AD.
References